metastatic rcc: using frontline ipilimumab/nivolumab
Published 6 years ago • 1.2K plays • Length 6:01Download video MP4
Download video MP3
Similar videos
-
1:34
fda approval of frontline nivolumab/ipilimumab combo in rcc
-
7:03
ipilimumab/nivolumab for favorable-risk mrcc
-
3:16
optimizing the use of ipilimumab/nivolumab in mrcc
-
7:36
mrcc patient selection for ipilimumab/nivolumab
-
1:08
dr. motzer on nivolumab/ipilimumab activity in rcc
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
0:52
dr. mckay on fda approval of nivolumab/ipilimumab in frontline rcc
-
0:51
dr. pal on the frontline approval of nivolumab and ipilimumab in mrcc
-
7:58
utilizing frontline bevacizumab in metastatic renal cell carcinoma
-
8:48
evaluating frontline systemic therapy for metastatic rcc
-
1:10
dr. motzer on first-line treatment of metastatic rcc
-
1:27
dr. hammers on nivolumab/ipilimumab data in rcc
-
1:26
dr. andre on nivolumab plus ipilimumab in dmmr/msi-h mcrc
-
3:07
checkmate-214: nivolumab/ipilimumab for mrcc?
-
2:00
nivolumab and ipilimumab in mrcc
-
0:39
dr. atkinson on when to use nivolumab monotherapy versus nivolumab/ipilimumab combination
-
1:16
dr. mcgregor on combination therapies with nivolumab, cabozantinib, and sunitinib in rcc
-
1:05
nivolumab and ipilimumab combination in frontline mcrc